Peritoneal Cancer Institute: Leading Innovation in the Treatment of Peritoneal Cancer
Peritoneal cancer has traditionally been one of the greatest challenges in oncology due to its difficult diagnosis and complex treatment. At the Peritoneal Cancer Institute (PCI), we are transforming this landscape through an innovative approach that combines advanced surgery with personalized therapies.
Located in Barcelona at the Teknon Medical Center, part of the QuirónSalud Group, we are among the pioneers in Europe in the comprehensive treatment of peritoneal cancer. Being based within one of the region’s leading hospitals enables us to provide patients with access to cutting-edge surgical techniques, including cytoreductive surgery with HIPEC and PIPAC, supported by multidisciplinary postoperative follow-up and personalized care.
With over 170 patients treated each year and a highly specialized team performing three cytoreductive surgery procedures with HIPEC every week, we have established ourselves as experts in the management of peritoneal carcinomatosis and related diseases such as Pseudomyxoma Peritonei (PMP), appendiceal and colorectal cancer, gastric cancer, mesothelioma, and gynecological malignancies, among others. Our multidisciplinary approach has made us a global benchmark in surgical innovation and comprehensive oncologic care.
Distinguished Physicians
Our team is led by Dr. Domenico Sabia, an oncologic surgeon with more than 20 years of experience in peritoneal neoplasms. He trained in general surgery at the Second University of Naples and the Reina Sofía University Hospital in Córdoba, and later specialized in cytoreductive surgery and HIPEC at leading institutions such as the National Cancer Institute in Milan and Georgetown University Hospital in Washington, D.C., where he worked alongside Dr. Paul Sugarbaker, a world pioneer in these techniques. Dr. Sabia currently directs the Peritoneal Oncologic Surgery Program at Teknon Medical Center, one of the most active and advanced centers in Europe in this field.
Dr. Lana Bijelic, Head of the Peritoneal Oncologic Surgery Unit at the Consorci Sanitari Integral (Barcelona), is an internationally recognized expert in cytoreductive surgery and malignant peritoneal neoplasms. She trained in Washington, D.C., specializing in oncologic surgery under the mentorship of Dr. Paul Sugarbaker in the United States. Before relocating to Spain in 2019, she founded a specialized program at the Inova Schar Cancer Institute. Dr. Bijelic has served on international oncology committees and coordinates the European School of Peritoneal Surface Oncology. She is board-certified by the American Board of Surgery and is widely recognized for her global contributions to research and medical education.
Dr. Jaume Capdevila is a specialist in the systemic treatment of gastrointestinal and endocrine tumors and an active member of numerous national and international scientific societies. He takes part in clinical research projects in collaboration with organizations such as EORTC, ESMO, ASCO, GEMCAD, and the Spanish Cooperative Group for Digestive Tumor Therapy.
Thanks to the dedication of these three physicians and a team trained alongside world leaders in cytoreductive surgery and HIPEC, the Peritoneal Cancer Institute has become an international center of excellence. Our high surgical volume translates into extensive experience and outstanding clinical outcomes. In addition, our location within the Teknon Medical Center provides access to an advanced, multidisciplinary clinical environment, where innovative techniques are combined with rigorous and specialized follow-up care